Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1914 2
1917 1
1922 1
1923 1
1925 1
1926 2
1945 5
1946 1
1947 3
1948 4
1949 4
1950 2
1951 3
1952 1
1954 2
1955 1
1956 1
1957 1
1958 1
1959 1
1961 1
1962 1
1963 1
1964 2
1967 1
1969 1
1970 3
1973 1
1974 4
1975 2
1976 3
1977 2
1978 4
1979 5
1980 3
1981 5
1982 3
1983 8
1984 5
1985 5
1986 6
1987 1
1988 5
1989 2
1990 3
1991 5
1992 5
1993 7
1994 4
1995 10
1996 7
1997 4
1998 5
1999 4
2000 10
2001 7
2002 3
2003 2
2004 3
2005 2
2006 7
2007 9
2008 10
2009 9
2010 12
2011 11
2012 13
2013 9
2014 9
2015 9
2016 12
2017 11
2018 17
2019 12
2020 15
2021 17
2022 26
2023 20
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

390 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Hoosh
Page 1
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Marso SP, et al. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. N Engl J Med. 2016. PMID: 27633186 Free article. Clinical Trial.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Free article. Clinical Trial.
Case 26-2017.
Letourneau AR, Price MC, Azar MM. Letourneau AR, et al. N Engl J Med. 2017 Aug 24;377(8):770-778. doi: 10.1056/NEJMcpc1616402. N Engl J Med. 2017. PMID: 28834480 No abstract available.
Visceral leishmaniasis in the COVID-19 pandemic era.
Paul A, Singh S. Paul A, et al. Trans R Soc Trop Med Hyg. 2023 Feb 1;117(2):67-71. doi: 10.1093/trstmh/trac100. Trans R Soc Trop Med Hyg. 2023. PMID: 36283121 Free PMC article. Review.
Visceral l eishmaniasis (VL), also known as kala-azar, had once been targeted for elimination in 2020, which now has been shifted to 2030. ...
Visceral l eishmaniasis (VL), also known as kala-azar, had once been targeted for elimination in 2020, which now has been shifted to …
Targeting Nrf2 in ischemia-reperfusion alleviation: From signaling networks to therapeutic targeting.
Sadrkhanloo M, Entezari M, Orouei S, Zabolian A, Mirzaie A, Maghsoudloo A, Raesi R, Asadi N, Hashemi M, Zarrabi A, Khan H, Mirzaei S, Samarghandian S. Sadrkhanloo M, et al. Life Sci. 2022 Jul 1;300:120561. doi: 10.1016/j.lfs.2022.120561. Epub 2022 Apr 20. Life Sci. 2022. PMID: 35460707 Review.
The I/R induces cell injury and organ dysfunction. The present review focuses on Nrf2 function in alleviation of I/R injury. Stimulating of Nrf2 signaling ameliorates I/R injury in various organs including lung, liver, brain, testis and heart. ...
The I/R induces cell injury and organ dysfunction. The present review focuses on Nrf2 function in alleviation of I/R injury. S …
Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
Carter JL, Su Y, Qiao X, Zhao J, Wang G, Howard M, Edwards H, Bao X, Li J, Hüttemann M, Yang J, Taub JW, Ge Y. Carter JL, et al. Biochem Pharmacol. 2023 Oct;216:115759. doi: 10.1016/j.bcp.2023.115759. Epub 2023 Aug 19. Biochem Pharmacol. 2023. PMID: 37604291
To better understand the mechanisms of resistance, we developed VEN + AZA-resistant AML cell lines, MV4-11/VEN + AZA-R and ML-2/VEN + AZA-R, which show > 300-fold persistent resistance compared to the parental lines. ...Inhibition of glycolysis with 2-Deoxy-D-glu …
To better understand the mechanisms of resistance, we developed VEN + AZA-resistant AML cell lines, MV4-11/VEN + AZA-R and ML-2/VEN + …
390 results